BioPharmSignal logoBioPharmSignal

Biotech News

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

Kymera (KYMR)KymeraClinical readout

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

Related news

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

KURAKura Oncology2026-10-13 11:30 EST

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

View all latest news

Kymera

Targeted Protein Degradation Kymera Therapeutics develops oral small-molecule degraders that recruit the cell’s protein-disposal machinery to remove disease-causing targets. The platform is intended to address proteins and pathways that are difficult to inhibit with conventional drugs. KT-621 KT-621 is a once-daily oral degrader of...

Recent company news

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Stock data

Close
128.12 USD
Market cap
5.86B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States